The results of a recent clinical trial conducted in hospitals across India found an anti-inflammatory drug used to treat rheumatoid arthritis improves health outcomes in severely ill COVID-19 patients.
Published in The Lancet Respiratory Medicine on March 4, 2021, researchers from the University of Bristol and Medanta Institute of Education and Research in India found evidence supporting the use of Tocilizumab (Actemra) in critically ill patients.
RA Drug Reduces Mortality Risk in Severely Ill COVID-19 Patients
Inflammatory Heart Disease After COVID-19 Rare in Athletes
Five athletes (0.6 percent) had cardiac magnetic resonance imaging findings suggestive of inflammatory heart disease
New Models Predict Risk for Ventilation, Death From COVID-19
Age not a predictor of which hospitalized COVID-19 patients will require ventilation
Neurologic Involvement Common in Children Hospitalized With COVID-19
Twelve percent of those with neurologic involvement develop life-threatening conditions associated with COVID-19
FDA Warns Consumers to Not Use Ivermectin for COVID-19
Agency has received reports of patients requiring medical support after self-medicating with ivermectin for use in horses
CDC Issues New Guidelines for Vaccinated Americans
Agency says fully vaccinated people can gather indoors with those who are also fully vaccinated
Nonprescription At-Home COVID-19 Test Receives Emergency Approval
The FDA also issued emergency use authorization for prescription at-home test kit for those suspected of COVID-19 within six days of symptom onset
AstraZeneca to Seek FDA Approval of COVID-19 Vaccine Within Weeks
If the two-dose vaccine is approved, it would be the fourth COVID-19 vaccine available in the United States